Matthew Pratt Whalen
CIK: 0002033867
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 12, 2026MIRA
MIRA PHARMACEUTICALS, INC.
Award(A)DirectStock Options (right to buy)
50K shares- - May 21, 2026TELO
Telomir Pharmaceuticals, Inc.
Award(A)DirectIncentive Stock Options (right to buy)
25K shares- - May 21, 2026TELO
Telomir Pharmaceuticals, Inc.
Disposition(D)DirectIncentive Stock Options (right to buy)
25K shares- - Apr 16, 2026TELO
Telomir Pharmaceuticals, Inc.
Award(A)DirectNon-Qualified Stock Options (right to buy)
50K shares- - Dec 9, 2024MIRA
MIRA PHARMACEUTICALS, INC.
Award(A)DirectStock Options (right to buy)
25K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  MIRA MIRA PHARMACEUTICALS, INC. | Award(A) Stock Options (right to buy) | 50,000 | - | - | Direct |
| May 21, 2026 |  TELO Telomir Pharmaceuticals, Inc. | Award(A) Incentive Stock Options (right to buy) | 25,000 | - | - | Direct |
| May 21, 2026 | TELO Telomir Pharmaceuticals, Inc. | Disposition(D) Incentive Stock Options (right to buy) | 25,000 | - | - | Direct |
| Apr 16, 2026 | TELO Telomir Pharmaceuticals, Inc. | Award(A) Non-Qualified Stock Options (right to buy) | 50,000 | - | - | Direct |
| Dec 9, 2024 | MIRA MIRA PHARMACEUTICALS, INC. | Award(A) Stock Options (right to buy) | 25,000 | - | - | Direct |
1-5 of 5 transactions
About Whalen Matthew Pratt
Whalen Matthew Pratt (SEC CIK 0002033867) files insider reports with the SEC as Director of Telomir Pharmaceuticals, Inc. (TELO) and Director of MIRA PHARMACEUTICALS, INC. (MIRA).
Signal8 holds 5 ownership filings by Whalen Matthew Pratt (1 Form 3, 4 Form 4), filed between Nov 26, 2024 and Jul 27, 2026. Those filings report 5 transactions, from Dec 9, 2024 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Whalen Matthew Pratt's filings is in MIAMI, FL.
Recent filings by Whalen Matthew Pratt
- Jun 12, 2026: Grant or award of MIRA derivative securities (Form 4, code A).
- May 21, 2026: Grant or award of TELO derivative securities (Form 4, code A).
- May 21, 2026: Disposition to issuer transaction of TELO derivative securities (Form 4, code D).
- Apr 16, 2026: Grant or award of TELO derivative securities (Form 4, code A).
- Dec 9, 2024: Grant or award of MIRA derivative securities (Form 4, code A).
Other insiders filing for Telomir Pharmaceuticals, Inc. (TELO)
- MacPherson Edward Clouston, Director
- Del Giudice Matthew Paul, Director
- Mushak Andriy, Chief Financial Officer
- Aminov Erez, CEO and Chairman
- MIRA PHARMACEUTICALS, INC., 10% Owner
- Weichselbaum Alan, Chief Financial Officer